Global Immune-mediated Necrotizing Myopathy Treatment market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Global Immune-mediated Necrotizing Myopathy Treatment Market Size, Share and Analysis

The global Immune-mediated Necrotizing Myopathy Treatment market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Immune-mediated necrotizing myopathy (IMNM) is a rare autoimmune muscle disease characterized by muscle inflammation and weakness. Treatment for immune-mediated necrotizing myopathy typically involves immunosuppressive therapies aimed at modulating or suppressing the immune response to reduce muscle inflammation and prevent further damage. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. LPI (LP Information) newest research report, the Immune-mediated Necrotizing Myopathy Treatment Industry Forecast looks at past sales and reviews total world Immune-mediated Necrotizing Myopathy Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Immune-mediated Necrotizing Myopathy Treatment sales for 2025 through 2031. With Immune-mediated Necrotizing Myopathy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immune-mediated Necrotizing Myopathy Treatment industry. This Insight Report provides a comprehensive analysis of the global Immune-mediated Necrotizing Myopathy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Immune-mediated Necrotizing Myopathy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Immune-mediated Necrotizing Myopathy Treatment market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune-mediated Necrotizing Myopathy Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune-mediated Necrotizing Myopathy Treatment. This report presents a comprehensive overview, market shares, and growth opportunities of Immune-mediated Necrotizing Myopathy Treatment market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Steroids &nbsp;&nbsp;&nbsp; Immunosuppressant &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; GlaxoSmithKline plc &nbsp;&nbsp;&nbsp; Dr. Reddys Laboratories &nbsp;&nbsp;&nbsp; Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) &nbsp;&nbsp;&nbsp; Hetero Drugs Limited &nbsp;&nbsp;&nbsp; AbbVie Inc. &nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries &nbsp;&nbsp;&nbsp; Novartis AG

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Market Size (2020-2031) &nbsp;2.1.2 Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Immune-mediated Necrotizing Myopathy Treatment by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Immune-mediated Necrotizing Myopathy Treatment Segment by Type &nbsp;2.2.1 Steroids &nbsp;2.2.2 Immunosuppressant &nbsp;2.2.3 Others &nbsp;2.3 Immune-mediated Necrotizing Myopathy Treatment Market Size by Type &nbsp;2.3.1 Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Type (2020-2025) &nbsp;2.4 Immune-mediated Necrotizing Myopathy Treatment Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Clinic &nbsp;2.4.3 Others &nbsp;2.5 Immune-mediated Necrotizing Myopathy Treatment Market Size by Application &nbsp;2.5.1 Immune-mediated Necrotizing Myopathy Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Application (2020-2025) 3 Immune-mediated Necrotizing Myopathy Treatment Market Size by Player &nbsp;3.1 Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share by Player &nbsp;3.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Player (2020-2025) &nbsp;3.1.2 Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Immune-mediated Necrotizing Myopathy Treatment Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Immune-mediated Necrotizing Myopathy Treatment by Region &nbsp;4.1 Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2020-2025) &nbsp;4.2 Global Immune-mediated Necrotizing Myopathy Treatment Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2020-2025) &nbsp;4.4 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2020-2025) &nbsp;4.5 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025) &nbsp;5.2 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2020-2025) &nbsp;5.3 Americas Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2020-2025) &nbsp;6.2 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2020-2025) &nbsp;6.3 APAC Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025) &nbsp;7.2 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2020-2025) &nbsp;7.3 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment by Region (2020-2025) &nbsp;8.2 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Immune-mediated Necrotizing Myopathy Treatment Market Forecast &nbsp;10.1 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2026-2031) &nbsp;10.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.1.3 APAC Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.1.4 Europe Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.1.5 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.2 Americas Immune-mediated Necrotizing Myopathy Treatment Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.2.2 Canada Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.2.3 Mexico Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.2.4 Brazil Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.3 APAC Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2026-2031) &nbsp;10.3.1 China Immune-mediated Necrotizing Myopathy Treatment Market Forecast &nbsp;10.3.2 Japan Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.3.3 Korea Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.3.4 Southeast Asia Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.3.5 India Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.3.6 Australia Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.4 Europe Immune-mediated Necrotizing Myopathy Treatment Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.4.2 France Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.4.3 UK Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.4.4 Italy Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.4.5 Russia Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.5 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.5.2 South Africa Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.5.3 Israel Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.5.4 Turkey Market Immune-mediated Necrotizing Myopathy Treatment Forecast &nbsp;10.6 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Type (2026-2031) &nbsp;10.7 Global Immune-mediated Necrotizing Myopathy Treatment Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Immune-mediated Necrotizing Myopathy Treatment Forecast 11 Key Players Analysis &nbsp;11.1 GlaxoSmithKline plc &nbsp;11.1.1 GlaxoSmithKline plc Company Information &nbsp;11.1.2 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Product Offered &nbsp;11.1.3 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 GlaxoSmithKline plc Main Business Overview &nbsp;11.1.5 GlaxoSmithKline plc Latest Developments &nbsp;11.2 Dr. Reddy's Laboratories &nbsp;11.2.1 Dr. Reddy's Laboratories Company Information &nbsp;11.2.2 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Product Offered &nbsp;11.2.3 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Dr. Reddy's Laboratories Main Business Overview &nbsp;11.2.5 Dr. Reddy's Laboratories Latest Developments &nbsp;11.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) &nbsp;11.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Information &nbsp;11.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Product Offered &nbsp;11.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Main Business Overview &nbsp;11.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Latest Developments &nbsp;11.4 Hetero Drugs Limited &nbsp;11.4.1 Hetero Drugs Limited Company Information &nbsp;11.4.2 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Product Offered &nbsp;11.4.3 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 Hetero Drugs Limited Main Business Overview &nbsp;11.4.5 Hetero Drugs Limited Latest Developments &nbsp;11.5 AbbVie Inc. &nbsp;11.5.1 AbbVie Inc. Company Information &nbsp;11.5.2 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Product Offered &nbsp;11.5.3 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 AbbVie Inc. Main Business Overview &nbsp;11.5.5 AbbVie Inc. Latest Developments &nbsp;11.6 Teva Pharmaceutical Industries &nbsp;11.6.1 Teva Pharmaceutical Industries Company Information &nbsp;11.6.2 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Product Offered &nbsp;11.6.3 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 Teva Pharmaceutical Industries Main Business Overview &nbsp;11.6.5 Teva Pharmaceutical Industries Latest Developments &nbsp;11.7 Novartis AG &nbsp;11.7.1 Novartis AG Company Information &nbsp;11.7.2 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Product Offered &nbsp;11.7.3 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 Novartis AG Main Business Overview &nbsp;11.7.5 Novartis AG Latest Developments 12 Research Findings and Conclusion

Report	Global Immune-mediated Necrotizing Myopathy Treatment Market Growth, Trends and Opportunities 2025-31
Selected License	Multi ID: LPI50790

Buyer Information

Order Summary